Biosergen AB (FRA:8N10) ROCE %: -314.20% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8N10 Biosergen AB FRA:8N10
18 GF Score
Price €0.51
View Full Analysis

What is Biosergen AB ROCE %?

Biosergen AB FRA:8N10 18 ROCE % is -314.20% as of Dec. 2025. GuruFocus rates FRA:8N10 with a GF Score™ of 18/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biosergen AB's annualized ROCE % for the quarter that ended in Dec. 2025 was -314.20%.

Biosergen AB  (FRA:8N10) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biosergen AB ROCE % Related Terms

Biosergen AB ROCE % Historical Data

* Premium members only.

The historical data trend for Biosergen AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosergen AB ROCE % Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -740.63 -152.92 -213.52 -75.89 -132.51

Biosergen AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.95 -46.01 -115.80 -184.67 -314.20
FRA:8N10
18GF Score
Biosergen AB FRA:8N10
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosergen AB ROCE % Calculation

Biosergen AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-3.493/( ( (4.61 - 0.419) + (1.822 - 0.741) )/ 2 )
=-3.493/( (4.191+1.081)/ 2 )
=-3.493/2.636
=-132.51 %

Biosergen AB's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-4.592/( ( (2.32 - 0.478) + (1.822 - 0.741) )/ 2 )
=-4.592/( ( 1.842 + 1.081 )/ 2 )
=-4.592/1.4615
=-314.20 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -314.20% mean?
Biosergen AB (FRA:8N10) has a ROCE % of -314.20% as of Dec. 2025.
Is Biosergen AB's ROCE % too high?
Biosergen AB's current ROCE % is -314.20%. Overall, Biosergen AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's ROCE % compare to VRTX and REGN?
Biosergen AB's ROCE % of -314.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Biosergen AB's current ROCE % is -314.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (FRA:8N10) has a current ROCE % of -314.20%. The current ROCE % is -314.20%. Biosergen AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Biosergen AB (FRA:8N10), the current ROCE % is -314.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosergen AB Business Description

Other Exchanges BIOSGN:Sweden
Address Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score

Get the complete analysis for FRA:8N10

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price